GT Biopharma

GTBP64

High Growth

$2.95arrow_drop_up3.32%$0.10

High Growth

Penny Stock

GTBP64

$2.95

arrow_drop_up3.32%$0.10

High Growth

Penny Stock

Performance History

Key Stats
Open	$3.03
Prev. Close	$3.01
EPS	-7.39
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$6.83M
PE Ratio	-

	LOW	HIGH
Day Range	2.92	3.11
52 Week Range	1.92	10.66

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-7.39

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About GT Biopharma (GTBP)

GT Biopharma Inc., also known as GTBP, is a biotechnology company focused on the development and commercialization of innovative cancer treatment therapies. The company is headquartered in Beverly Hills, California and is listed on the OTCQB under the ticker symbol GTBP. GTBP's mission is to develop safe and effective therapies that can improve the lives of cancer patients worldwide.

GTBP's stock price history shows that the company's shares have experienced significant volatility over the years. The price has ranged from a low of $0.05 to a high of $3.50 per share. Investors should carefully consider the risks associated with investing in a biotech company, as the stock price can be affected by factors such as clinical trial results, regulatory approval, and market conditions.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Michael Martin Breen
Headquarters: Brisbane
Employees: 2
Exchange: NASDAQ

Keep an eye on GT Biopharma

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is GT Biopharma's (GTBP) price per share?

The current price per share for GT Biopharma (GTBP) is $2.95. The stock has seen a price change of $0.1 recently, indicating a 3.32% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for GT Biopharma (GTBP)?

For GT Biopharma (GTBP), the 52-week high is $10.66, which is 261.36% from the current price. The 52-week low is $1.92, the current price is 53.65% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is GT Biopharma (GTBP) a growth stock?

GT Biopharma (GTBP) has shown an average price growth of -6.03% over the past three years. It has received a score of 97 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying GT Biopharma as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is GT Biopharma (GTBP) stock price performance year to date (YTD)?

As of the latest data, GT Biopharma (GTBP) has a year-to-date price change of -61.44%. Over the past month, the stock has experienced a price change of 16.14%. Over the last three months, the change has been 36.57%. Over the past six months, the figure is -41.24%.

help

Is GT Biopharma (GTBP) a profitable company?

GT Biopharma (GTBP) has a net income of -$7.6M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$13.58M. Furthermore, the EBITDA is $0.

help

What is the market capitalization of GT Biopharma (GTBP)?

GT Biopharma (GTBP) has a market capitalization of $6.84M. The average daily trading volume is 3.01, indicating the stock's liquidity and investor engagement.

News

PRESS RELEASES

Jun 27, 2024

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

PRESS RELEASES

May 21, 2024

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

PRESS RELEASES

Mar 26, 2024

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session

PRESS RELEASES

Feb 1, 2024

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

PRESS RELEASES

Dec 6, 2023

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders

Performance History

Score Breakdown

Welcome to Stocklytics

Analyst Forecast

Analyst Ratings

About GT Biopharma (GTBP)

Keep an eye on GT Biopharma

Frequently Asked Questions

What is GT Biopharma's (GTBP) price per share?

What is the 52-week high and low for GT Biopharma (GTBP)?

Is GT Biopharma (GTBP) a growth stock?

What is GT Biopharma (GTBP) stock price performance year to date (YTD)?

Is GT Biopharma (GTBP) a profitable company?

What is the market capitalization of GT Biopharma (GTBP)?

News

Take Your Investments to a Whole New Level